• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢肿瘤中的纤溶酶原激活剂

Plasminogen activators in ovarian tumours.

作者信息

Svanberg L, Linell F, Pandolfi M, Astedt B

出版信息

Acta Pathol Microbiol Scand A. 1975 Mar;83(2):193-8. doi: 10.1111/j.1699-0463.1975.tb01374.x.

DOI:10.1111/j.1699-0463.1975.tb01374.x
PMID:1146550
Abstract

Ovarian tumours obtained at laparotomy were histochemically examined for their local fibrinolytic activity, and simultaneous fibrin/fibrinogen degradation products (FDP) were determined in the serum. The fibrinolytic activity was confined mainly to vessels of both malignant and benign tumours. A very close correlation was demonstrated between the fibrinolytic activity and the vascularity of the sections. FDP were found in the serum in 13 of 14 patients with malignant tumours, but in none with benign tumours. The difference in occurrence of FDP in patients with malignant and benign tumours might be due to the invasive growth of the former with the entrance of thromboplastic substances, fibrinolytic activators or locally formed FDP into the bloodstream.

摘要

对剖腹手术时获取的卵巢肿瘤进行组织化学检查,以检测其局部纤维蛋白溶解活性,并同时测定血清中的纤维蛋白/纤维蛋白原降解产物(FDP)。纤维蛋白溶解活性主要局限于恶性和良性肿瘤的血管。切片的纤维蛋白溶解活性与血管形成之间显示出非常密切的相关性。14例恶性肿瘤患者中有13例血清中发现有FDP,但良性肿瘤患者均未发现。恶性和良性肿瘤患者FDP出现情况的差异可能是由于前者的浸润性生长,导致促凝物质、纤维蛋白溶解激活剂或局部形成的FDP进入血流。

相似文献

1
Plasminogen activators in ovarian tumours.卵巢肿瘤中的纤溶酶原激活剂
Acta Pathol Microbiol Scand A. 1975 Mar;83(2):193-8. doi: 10.1111/j.1699-0463.1975.tb01374.x.
2
Release of fibrinolytic activators from human ovarian tumours in organ culture.
Ann Chir Gynaecol. 1976;65(6):405-7.
3
The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.对安克洛治疗的纤溶反应:纤维蛋白原和纤维蛋白降解产物的特征
Br J Haematol. 1993 Feb;83(2):276-81. doi: 10.1111/j.1365-2141.1993.tb08283.x.
4
Fibrin degradation products and ovarian tumours.纤维蛋白降解产物与卵巢肿瘤
Br Med J. 1971 Nov 20;4(5785):458-9. doi: 10.1136/bmj.4.5785.458.
5
Fibrinolytic activity in coronary heart disease.冠心病中的纤溶活性。
Chin Med J (Engl). 1989 Sep;102(9):660-3.
6
Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.急性心肌梗死溶栓治疗期间纤维蛋白降解产物的评估
Circulation. 1986 Nov;74(5):1027-36. doi: 10.1161/01.cir.74.5.1027.
7
New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.使用单克隆抗体对血浆中纤维蛋白-纤维蛋白原降解产物进行新型酶免疫测定。
J Lab Clin Med. 1987 Jan;109(1):75-84.
8
[Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
Cas Lek Cesk. 1990 Oct 26;129(43):1349-51.
9
Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
Ann Chir Gynaecol. 1977;66(3):131-134.
10
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.卵巢癌患者血液和肿瘤液中的纤溶酶原激活剂及纤溶酶原激活剂抑制剂
Eur J Cancer. 1994;30A(9):1302-9. doi: 10.1016/0959-8049(94)90178-3.

引用本文的文献

1
Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall.组织型纤溶酶原激活物和尿激酶在血管壁中的免疫组织化学定位。
J Clin Pathol. 1985 Feb;38(2):140-5. doi: 10.1136/jcp.38.2.140.